| answer text |
<p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply
the United Kingdom with pharmacy (P) or prescription-only medicines (POM) from, or
via, the European Union/European Economic Area (EEA), asking them to ensure they have
a minimum of six weeks’ additional supply in the UK, over and above their business
as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU
Exit.</p><p> </p><p>Over-the-counter ‘General Sales List’ (GSL) medicines are not
included in the Department’s medicines supply contingency programme. GSLs are not
considered in-scope for the programme as there are multiple alternatives available
should a single GSL medicine be subject to a short-term supply disruption.</p><p>
</p><p>The Department is currently considering how best it may support pharmaceutical
companies as part of its medicine supply contingency programme. Part of this support
will include funding to provide additional capacity for the storage of P and POM medicines
in the UK. A process to apply for such funding has been undertaken in recent weeks
and contract agreements are imminent.</p>
|
|
